The LA PEP program (Latin American Professional Exchange Program) got started a week ago! This program aims to identify aspiring young health professionals working in the HD communities we serve, and facilitate fellowships for them to get training experience at leading HD institutions and hospitals in Spain, Colombia, and Chile.…

Improving access to healthcare has been at the core of Factor-H’s mission since its inception, knowing that health systems are usually under-prepared to optimally serve the rare diseases, and the situation in which HD families live in many regions of Latin-America makes the situation even more complex. The strategic planning…

The LA PEP program’s main objective is to provide educational opportunities to health professionals that work in Latin American enclaves with a high incidence of Huntington’s disease. Health & Disease Management is one of the main areas of focus of Factor-H and one of the main programs is what we call LA…

Objectives of the Clinical Practice Guidelines for the Management of Huntington’s Disease in Latin America In 2020, Factor-h obtained a grant from Roche for a project to generate an evidence-based clinical consensus for Latin America countries. The general objective of this consensus is to approach the health problems and improve the…

   

Factor-H has established formal collaborations with the University of Antioquia and the University of Medellín in Medellín (State of Antioquia), and the University Metropolitana (Barranquilla, State of Atlántico) to assist caregivers and the patients we directly support in Colombia (currently >130 families). Our employees work only in defined regions of…

El presidente de Factor-H expone su primera reacción y hace un primer análisis tras la noticia de la suspensión de los estudios de Fase III de Roche con Tominerse, y expone un resumen de los programas que siguen activos. Estimados amigas y amigos, esta semana ha sido una de las…

Si me hubiesen preguntado hace unos años que en el 2020 empezaríamos estudios clínicos con una terapia en pastilla que trataría la causa de la enfermedad, no me lo hubiera creído. Durante mucho tiempo, desde que empecé a trabajar como científico en la fundación CHDI, he trabajado mucho en el…

En las últimas semanas ha habido algunas noticias en la prensa sobre la progresión en fases clínicas de varios agentes potencialmente terapéuticos para tratar la enfermedad de Huntington. Estos avances continúan llamando la atención general y de los especialistas médicos, por el sencillo hecho de que este tipo de terapias…

MEETING BETWEEN THE MARACAIBO PATIENT ASSOCIATIONS, FACTOR-H AND FUNDACION HABITAT LUZ … THE BEGINNING OF OUR EFFORTS TO BRING CHANGE TO THE COMMUNITIES MOST AFFECTED BY HD IN THE WORLDHappy New Year 2018!On Monday December 11th, we held an all-day meeting in the offices of Fundacion Habitat Luz, a Maracaibo,…